Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cheongju-si
Clinical trial register · South Korea

Clinical Trials in Cheongju-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca32 Merck Sharp & Dohme LLC12 Janssen Research & Development, LLC9 Eli Lilly and Company9 Daiichi Sankyo8
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Cheongju-si

184 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Bristol-Myers Squibb
Phase 3
850
Cheongju-si, Buk-Gu, Dalseo, Goyang-si, Seongnam-si, Hwasun-Gun, Seocho -Gu, Songpa-Gu
2026-09-08
Not yet open
Chonnam National University Hospital
Not applicable
1,252
Bucheon-si, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Gwangju
2026-09-01
Not yet open
Multiple Ascending Dose Study of DW4421
NCT07691242Healthy Adult Volunteers
DrugsDW4421S·DW4421S-T1
Daewon Pharmaceutical Co., Ltd.
Phase 1
56
Cheongju-si
2026-09
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1
24
Cheongju-si, Seoul
2026-07-14
Not yet open
Korea United Pharm. Inc.
Phase 1
60
Cheongju-si
2026-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Goyang-si, Suwon, Cheongju-si, Daegu, Seoul
2026-06-18
Recruiting
BeOne Medicines
Phase 3
1,056
HaeundaeGu, Seogu, Cheongju-si, Cheonansi, Dalseogu, BundangGu SeongnamSi, DanwonGu AnsanSi, IlsandongGu GoyangSi
2026-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul
2026-05-04
Recruiting
Bristol-Myers Squibb
Phase 3
850
Cheongju-si, Seongnam, Seoul
2026-03-16
Not yet open
Daewon Pharmaceutical Co., Ltd.
Phase 1
38
Cheongju-si
2026-03-06
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Cheongju-si, Gwangju, Incheon, Seoul, Wŏnju
2026-03-03
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Cheongju-si, Incheon, Seongnam-si, Seoul, Suwon
2026-02-17
Not yet open
Daewon Pharmaceutical Co., Ltd.
Phase 1
48
Cheongju-si
2026-02-01
Not yet open
Daewon Pharmaceutical Co., Ltd.
Phase 1
36
Cheongju-si
2026-02
Recruiting
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
NCT07687706Ischemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular Disease
DrugTegoprazan
Hanyang University Guri Hospital
Phase 3
1,524
Busan, Daegu, Chuncheon, Anyang-si, Iksan, Jeonju, Cheongju-si, Guri-si
2026-01-26
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul
2026-01-02
By invitation
Daewon Pharmaceutical Co., Ltd.
Phase 1
38
Cheongju-si
2025-12-28
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Daegu, Seongnam-si, Suwon, Cheongju-si, Goyang-si, Pusan, Yangsan, Jinju
2025-12-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Goyang-si, Seongnam-si, Cheongju-si, Seoul
2025-12-12
Recruiting
AbbVie
Phase 2/3
490
Goyang-si, Cheongju-si, Seoul
2025-12-10
Recruiting
Daewon Pharmaceutical Co., Ltd.
Phase 1
150
Cheongju-si
2025-12-01
Recruiting
AbbVie
Phase 2
180
Goyang-si, Cheongju-si, Seoul
2025-11-25
Recruiting
AstraZeneca
Phase 2
435
Anyang-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Ulsan
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul
2025-11-05
Recruiting
BioNTech SE
Phase 3
558
Cheonan, Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Busan, Cheongju-si, Daegu, Seoul
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Pfizer
Phase 3
680
Cheongju-si, Goyang-si, Seongnam, Seongnam-si, Suwon, Haeundae-gu, Dongjak-gu, Seoul
2025-09-29
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Anyang-si, Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Gwangju
2025-09-22
Active, closed
Celltrion
Phase 1
218
Busan, Seongnam-si, Cheongju-si, Seoul
2025-09-17
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Cheongju-si, Gangnam Gu, Seongnam-si, Seoul
2025-09-10
Recruiting
Seoul National University Bundang Hospital
Phase 2
130
Busan, Daegu, Gangneung, Seongnam-si, Incheon, Hwasun, Cheongju-si, Seoul
2025-08-27
Recruiting
AstraZeneca
Phase 2
278
Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-08-07
Recruiting
AbbVie
Phase 2/3
854
Busan, Cheongju-si, Seoul
2025-08-03
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cheongju-si, Goyang-si, Incheon, Seoul
2025-07-17
Recruiting
Asan Medical Center
Phase 4
2,340
Seoul, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon
2025-07-10
Not yet open
Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea
NCT07037303Bronchiectasis, Bronchiectasis With Acute Exacerbation
Chungbuk National University Hospital
Not applicable
100
Cheongju-si
2025-07-01
Recruiting
Novo Nordisk A/S
Phase 2
200
Cheongju-si, Daegu, Gangwon-do, Seongnam-si, Gyeonggi-do, Seoul
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Anyang-si, Cheongju-si, Chuncheon, Daegu, Jeonju, Seongnam-si, Seoul, Wŏnju
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Cheongju-si, Daegu, Gangwon-do, Seongnam-si, Gyeonggi-do, Seoul
2025-06-27
Not yet open
Next Biomedical Co., Ltd.
Not applicable
60
Cheongju-si, Daejeon, Gwangju, Sejong, Seoul, Yangsan
2025-06
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Goyang-si, Seongnam-si, Suwon, Hwasungun, Cheongju-si, Seocho-gu, Daegu, Incheon
2025-05-22
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gyeonggi-do, Cheongju-si, Hwasun, Seoul
2025-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Cheongju-si, Namdong-gu, Yangsan, Busan, Seoul
2025-04-24
Recruiting
Eli Lilly and Company
Phase 3
700
Bupyeong-gu, Busan, Cheongju-si, Daegu, Deagu, Eunpyeong-gu, Gangnam-gu, Goyang-si
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Cheongju-si, Daegu, Seoul
2025-03-26
Recruiting
AstraZeneca
Phase 3
11,300
Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan
2025-03-14
Recruiting
BioNTech SE
Phase 2
60
Jinju, Cheongju-si, Incheon, Seoul
2025-03-03
Recruiting
Daiichi Sankyo
Phase 3
726
Cheongju-si, Daegu, Goyang-si, Hwasun-gun, Incheon, Jeonju, Seongnam, Seongnam-si
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Cheongju-si, Seongnam, Suwon, Seoul, Daegu
2025-02-25
Recruiting
BioNTech SE
Phase 3
621
Seoul, Goyang-si, Suwon, Jinju, Incheon, Cheongju-si
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Active, closed
Genmab
Phase 3
191
Suwon, Cheongju-si, Daegu, Goyang-si, Seoul
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Cheongju-si, Jinju, Seoul
2024-11-22
Recruiting
AstraZeneca
Phase 3
1,160
Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
2024-11-18
Active, closed
Eli Lilly and Company
Phase 3
1,400
Busan, Cheongju-si, Gangnam-gu, Gangseo-gu, Gwangju, Incheon, Jeju City, Namdong-gu
2024-10-24
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
NCT06649240Ischemic Stroke, Small Vessel Cerebrovascular Disease, Cholesterol, LDL, Secondary Prevention
DrugsBiweekly·Ezetimibe
Seoul National University Hospital
Not applicable
4,016
Ansan, Anyang, Busan, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon
2024-10-04
Recruiting
Yuhan Corporation
Phase 1/2
201
Seongnam-si, Suwon, Cheongju-si, Seoul
2024-10-02
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Cheongju-si, Seongnam-si, Incheon, Seoul, Busan, Daegu, Gyeonggi-do, Ulsan
2024-09-27
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Suwon, Jeonju, Cheongju-si, Busan, Incheon, Seoul
2024-09-12
Active, closed
Amgen
Phase 3
315
Suwon, Jeonju, Cheongju-si, Seoul
2024-09-09
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Ansan-si, Busan, Cheonan-si, Cheongju-si, Daegu, Deagu, Goyang-si, Guri-si
2024-08-30
Active, closed
BioNTech SE
Phase 2
110
Cheongju-si, Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Wŏnju, Gwangju, Seongnam, Suwon, Cheongju-si, Busan, Haeundae-gu, Daegu
2024-08-05
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Cheongju-si, BundangGu SeongnamSi, Seongnam-si, GangnamGu, SeodaemunGu, Seoul, SongpaGu
2024-07-23
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Bucheon-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Busan, Cheongju-si, Daegu
2024-06-25
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bucheon-si, Busan, Cheongju-si, Daejeon, Deagu, Gwangju, Incheon, Seongnam
2024-06-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Goyang-si, Seongnam, Suwon, Pusan, Cheongju-si, Busan, Daegu, Junggu
2024-06-11
Recruiting
Daiichi Sankyo
Phase 3
540
Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Seongnam-si, Busan, Goyang-si, Seoul, Cheongju-si, Incheon, Suwon
2024-05-20
Active, closed
AstraZeneca
Phase 2
76
Cheongju-si, Seongnam-si, Seoul, Suwon
2024-04-21
Recruiting
AstraZeneca
Phase 3
3,850
Anyang-si, Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gwangmyeong
2024-04-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2024-04-03
Recruiting
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc
Phase 1/2
315
Seongnam-si, Suwon, Cheongju-si, Seoul
2024-03-26
Active, closed
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT05995600Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack, Cerebrovascular Disease
DrugWarfarin
Seoul National University Hospital
Phase 4
200
Anyang, Busan, Cheongju-si, Chuncheon, Daegu, Daejeon, Guri-si, Gwangju
2024-02-20
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Cheongju-si, Incheon, Seoul
2024-02-16
Recruiting
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
NCT05910827Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
DrugsHMBD-001·Cetuximab·Docetaxel
Hummingbird Bioscience
Phase 1/2
398
Cheongju-si, Seongnam-si, Seoul, Suwon
2024-02-05
Recruiting
Colorado Prevention Center
Phase 3
5,200
Gwangju, Wŏnju, Seoul, Bucheon-si, Incheon, Daejeon, Cheongju-si, Busan
2024-01-17
Recruiting
Eli Lilly and Company
Phase 3
1,264
Cheongju-si, Daegu, Deagu, Gangnam-gu, Goyang-si, Hwasun, Seoul, Suwon
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Cheongju-si, Seongnam, Seoul
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Wŏnju, Goyang-si, Suwon, Cheongju-si, Daegu, Seoul
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2023-12-06
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Cheongju-si, Incheon, Seoul
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Recruiting
AbbVie
Phase 1
325
Busan, Jinju, Cheongju-si, Seoul
2023-11-09
Active, closed
AstraZeneca
Phase 3
895
Cheongju-si, Incheon, Jinju, Seoul, Suwon
2023-10-24
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Cheongju-si, Seongnam-si, Seoul
2023-09-26
Active, closed
Boehringer Ingelheim
Phase 2
268
Cheongju-si, Seoul
2023-09-08
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-08-08
Active, closed
Hoffmann-La Roche
Phase 3
459
Anyang-si, Bucheon-si, Cheongju-si, Gyeonggi-do, Seongnam-si, Seoul
2023-08-08
Recruiting
J Ints Bio
Phase 1/2
150
Goyang-si, Cheongju-si, Seoul, Suwon
2023-07-30
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Incheon, Suwon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-06-30
Active, closed
OncoC4, Inc.
Phase 3
630
Cheongju-si, Daegu, Goyang-si, Seoul, Suwon
2023-06-28
Active, closed
Janssen Research & Development, LLC
Phase 2
68
Cheongju-si, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2023-05-18
Active, closed
AstraZeneca
Phase 3
37
Cheongju-si, Goyang-si, Seongnam-si, Seoul, Tonggu
2023-05-08
Active, closed
Klus Pharma Inc.
Phase 2
356
Suwon, Cheongju-si, Seoul, Busan
2023-04-19
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Anyang-si, Busan, Cheonan-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Goyang-si
2023-04-11
Active, closed
AstraZeneca
Phase 3
94
Cheongju-si, Junggu, Seoul
2023-04-05
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Busan, Cheongju-si, Daegu, Gyeonggi-do, Jeollanam-do, Seoul
2023-03-23
Recruiting
Seoul National University Hospital
Phase 4
11,086
Seoul, Andong, Busan, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu
2023-03-22
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Cheongju-si, Goyang, Gwangju, Gyeonggi-do, Seogu, Seoul
2023-03-16
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Not applicable
2,400
Anyang, Bucheon-si, Busan, Changwon, Cheongju-si, Daegu, Gangneung, Iksan
2023-03-13
Active, closed
BeiGene
Phase 2
400
Cheongju-si, IlsandongGu GoyangSi, PaldalGu SuwonSi, Seongnam-si, GangnamGu, SeodaemunGu, SongpaGu
2023-03-07
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Active, closed
Gilead Sciences
Phase 2
400
Changwon-Si, Cheongju-si, Hwasun-gun, Seoul
2023-02-21
Recruiting
Abion Inc
Phase 2
178
Goyang-si, Suwon, Dongjak, Seoul, Sinchon-dong, Cheongju-si, Incheon, Jinju
2023-01-17
Active, closed
Daiichi Sankyo
Phase 3
1,170
Cheongju-si, Daegu, Gangnam-Gu, Goyang-si, Jinju-si Gyeongsangnam-do, Seongnam-si, Seoul
2023-01-11
Active, closed
AstraZeneca
Phase 3
1,350
Busan, Cheongju-si, Jinju, Seoul, Suwon
2022-12-29
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Cheongju-si, Goyang-si, Incheon, Jeollanam-do, Seongnam, Seoul
2022-12-13
Active, closed
Eli Lilly and Company
Phase 3
8,000
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Gyeongsan-si, Hwasun-gun, Incheon
2022-10-04
Active, closed
AstraZeneca
Phase 3
594
Cheongju-si, Seoul, Suwon
2022-09-15
Recruiting
Yuhan Corporation
Phase 1/2
147
Seongnam-si, Suwon, Jinju, Cheongju-si, Incheon, Seoul, Ulsan
2022-08-26
Active, closed
Genentech, Inc.
Phase 3
373
Cheongju-si, Dongnam-gu, Cheonan-si, Goyang-si, Seongnam-si, Seoul
2022-08-03
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Cheongju-si, Seoul
2022-08-03
Active, closed
Drug-Coated Balloon in Patients With High Bleeding Risk
NCT05221931Coronary Artery Disease
Samsung Medical Center
Not applicable
1,359
Ansan, Cheongju-si, Daegu, Gangneung, Gwangju, Gwangmyeong, Incheon, Jinju
2022-07-29
Active, closed
Daiichi Sankyo
Phase 3
586
Cheongju-si, Goyang, Seongnam, Seoul
2022-07-08
Recruiting
Adagene Inc
Phase 1/2
186
Seogu, Seongnam, Suwon, Cheongju-si, Seoul, Daegu
2022-06-15
Recruiting
Astellas Pharma Inc
Phase 1
681
Goyang-si, Seongnam-si, Cheongju-si, Jongno -Gu, Seodaemun-gu, Songpa-gu, Seoul
2022-06-08
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Busan, Cheongju-si, Gyeonggi-do, Seongnam, Seongnam-si, Seoul
2022-05-30
Active, closed
Gilead Sciences
Phase 2
193
Cheongju-si, Inchon, Seoul, Suwon
2022-05-30
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
Cheongju-si, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2022-03-10
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul, Busan, Incheon
2022-03-07
Active, closed
Daiichi Sankyo
Phase 3
740
Seongnam-si, Jinju, Cheongju-si, Daegu, Goyang-si, Seoul, Songpa-gu
2022-03-04
Active, closed
AstraZeneca
Phase 3
1,051
Changwon-si, Cheongju-si, Seongnam-si, Seoul, Suwon
2022-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Active, closed
Hoffmann-La Roche
Phase 3
660
Cheongju-si, Daegu, Gyeongsangnam-do, Seongnam-si, Seoul, Ulsan
2021-11-18
Active, closed
AstraZeneca
Phase 3
454
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2021-10-28
Active, closed
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Bundang Gu, Seoul, Cheongju-si, Busan, Taegu
2021-09-20
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Cheongju-si, Gangwon-do, Gyeonggi-do, Incheon, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
110
Seongnam, Cheongju-si, Seoul
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gangseo-gu, Goyang-si, Incheon
2021-08-14
Active, closed
ALX Oncology Inc.
Phase 2
172
Cheongju-si, Daegu, Incheon, Seongnam, Seongnam-si, Seoul
2021-05-10
Active, closed
IDEAYA Biosciences
Phase 1
169
Goyang-si, Seongnam-si, Cheongju-si, Seoul
2021-04-14
Active, closed
ALX Oncology Inc.
Phase 2
189
Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon
2021-04-02
Recruiting
AstraZeneca
Phase 1
304
Cheongju-si, Goyang-si, Jinju, Seoul
2021-03-09
Active, closed
AstraZeneca
Phase 2
31
Cheongju-si, Jinju, Seoul
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Busan, Cheongju-si, Daegu, Hwasun-gun, Incheon, Junggu, Seongnam-si, Seoul
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Songpa-gu, Cheongju-si, Daegu, Goyang-si, Seongnam, Seoul
2021-02-02
Active, closed
Daiichi Sankyo
Phase 3
605
Cheongju-si, Daegu, Gyeonggi-do, Seongnam-si, Seoul
2020-12-21
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Busan, Cheongju-si, Daegu, Goyang-si, Junggu, Seoul, Suwon
2020-12-02
Active, closed
Janssen Research & Development, LLC
Phase 1
158
Cheongju-si, Seongnam-si, Seoul
2020-11-10
Active, closed
Hoffmann-La Roche
Phase 3
992
Cheongju-si, Daegu, Gyeonggi-do, Incheon, Seoul, Ulsan
2020-10-09
Active, closed
AstraZeneca
Phase 3
370
Busan, Cheongju-si, Goyang-si, Seongnam-si, Seoul
2020-10-02
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Busan, Cheongju-si, Seongnam-si, Seoul
2020-09-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Goyang-si, Seongnam-si, Suwon, Jinju, Cheongju-si, Daegu, Seoul
2020-07-06
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Goyang-si, Cheongju-si, Seoul
2020-06-08
Active, closed
Takeda
Phase 3
354
Cheongju-si, Busan, Goyang, Jeongnam, Seoul
2020-01-10
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
Gyeonggi-do, Seongnam-si, Suwon, Pusan, Hwasun, Incheon, Cheongju-si, Busan
2020-01-07
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Cheongju-si, Jeonju, Namdong, Seoul, Yangsan
2019-09-17
Active, closed
Biogen
Observational
74
Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gwangju, Jeonju, Seoul
2019-07-02
Active, closed
AstraZeneca
Phase 3
587
Cheongju-si, Goyang-si, Seoul
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2019-06-25
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Cheongju-si, Daejeon, Goyang, Incheon, Seoul
2019-03-22
Active, closed
AstraZeneca
Phase 3
724
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2019-03-06
Active, closed
AstraZeneca
Phase 1
175
Cheongju-si, Seoul
2018-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi
2018-12-07
Active, closed
AstraZeneca
Phase 3
825
Busan, Cheongju-si, Seongnam-si, Seoul, Suwon
2018-12-06
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Active, closed
AstraZeneca
Phase 3
730
Changwon-si, Cheongju-si, Daegu, Goyang-si, Jinju, Seongnam-si, Seoul, Suwon
2018-09-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Inceon, Hwasun, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Gangnam-gu, Songpagu
2018-08-21
Active, closed
AstraZeneca
Phase 3
216
Cheongju-si, Incheon, Seongnam-si, Seoul
2018-07-19
Active, closed
MedImmune LLC
Phase 1
400
Cheongju-si, Gyeonggi-do, Incheon, Seoul
2018-04-24
Active, closed
AstraZeneca
Phase 2
273
Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2018-03-07
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Observational
4,000
Anyang, Bucheon-si, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung
2018-01-11
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Busan, Daegu, Daejeon
2017-12-18
Active, closed
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Active, closed
AstraZeneca
Phase 3
987
Changwon, Cheongju-si, Daegu, Incheon, Jinju, Seongnam-si, Seoul
2017-03-27
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Seoul, Hwasun-eup, Hwasun-gun, Cheongju-si
2017-03-07
Active, closed
AstraZeneca
Phase 3
669
Changwon-si, Cheongju-si, Daegu, Incheon, Jinju, Seoul, Suwon
2017-01-02
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Cheongju-si, Goyang-si, Incheon, Seongnam-si, Seoul
2016-05-24
Active, closed
AstraZeneca
Phase 3
682
Cheongju-si, Seoul, Suwon
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Active, closed
Eli Lilly and Company
Phase 3
545
Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan
2015-05-06
Active, closed
AstraZeneca
Phase 1
344
Cheongju-si, Goyang-si, Seongnam-si, Seoul
2014-08-05
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Yangsan, Busan, Changwon, Cheongju-si, Daegu, Daejeon, Gangneung, Gwangju
2012-01
Recruiting
Seung-Jung Park
Observational
20,000
Anyang, Bucheon-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2011-06
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327Coronary Artery Disease
Seung-Jung Park
Observational
10,000
Anyang, Bucheon-si, Busan, Cheonan, Cheongju-si, Daegu, Daejeon, Gangneung
2007-07
Recruiting
Medtronic
Observational
20,000
Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Jeonju, Seongnam-si
1983-01
Rows per page Showing 1–184 of 184
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/cheongju-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 184 of those studies with a site in Cheongju-si.

How many clinical trials are recruiting in Cheongju-si?

83 of the 184 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 91 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cheongju-si), 184 studies
PhaseStudiesRecruitingShare
Phase 3943951.1%
Phase 2301116.3%
Phase 120610.9%
Phase 1/216128.7%
Phase 2/3964.9%
Not applicable623.3%
Observational653.3%
Phase 4321.6%

Most active sponsors

Lead sponsors with the most studies (Cheongju-si)
Lead sponsorStudiesRecruiting
AstraZeneca328
Merck Sharp & Dohme LLC126
Eli Lilly and Company94
Janssen Research & Development, LLC91
Daiichi Sankyo83
AbbVie75
Bristol-Myers Squibb76
Daewon Pharmaceutical Co., Ltd.61
BioNTech SE54
Hoffmann-La Roche51
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.